Purpose

Less local availability and higher skin permeation restrict wide application of silver sulfadiazine (SSD) formulations against infectious burn wound.

Aim

We aimed to develop β-cyclodextrin inclusion complex-based in situ pluronic gel of SSD (β-CD-ssd P-Gel).

Methods

Formation of inclusion complex was confirmed by FT-IR, DSC, SEM, and XRD and checked for improved solubility.

Results and Discussion

Poloxamer (407/118)-based in situ gel of inclusion complex was prepared and characterized for its gelation temperature (33.50 °C), viscosity (1159.25 ± 5.60 cps), pH (6.4 ± 0.56), and drug content (91.56 ± 1.62%). The developed gel showed slow drug release and slow permeation of the drug through the skin. It showed broader zone of Staphylococcus aureus growth inhibition (31 ± 0.20 mm) and high wound contraction (98.89%) when compared with the marketed formulation (26 ± 0.20 mm and 58.00%, respectively).

Conclusions

A consistent, biocompatible, β-CD-ssd P-Gel was prepared successfully. It was found able to ensure increased local availability by forming viscous gel below body temperature, high SSD availability at the desired site, and high efficacy against infectious wound.

中文翻译：

---

磺胺嘧啶银原位凝胶改善感染性烧伤创面疗效的研究与评价

目的

较少的局部可用性和较高的皮肤渗透性限制了磺胺嘧啶银（SSD）制剂在感染性烧伤创面方面的广泛应用。

目标

我们旨在开发基于β-环糊精包合物的SSD原位普朗尼克凝胶（β-CD-ssdP-Gel）。

方法

FT-IR，DSC，SEM和XRD证实了包合物的形成，并检查了溶解度的提高。

结果和讨论

制备了基于泊洛沙姆（407/118）的包合复合物原位凝胶，并对其凝胶化温度（33.50°C），粘度（1159.25±5.60 cps），pH（6.4±0.56）和药物含量（91.56±1.62）进行了表征％）。显影的凝胶显示出缓慢的药物释放和缓慢的药物透过皮肤渗透。与市售制剂（分别为26±0.20 mm和58.00％）相比，它显示了更广泛的金黄色葡萄球菌生长抑制区域（31±0.20 mm）和高伤口收缩（98.89％）。

结论

成功制备了一致的生物相容性β-CD-ssdP-凝胶。发现能够通过在低于体温的温度下形成粘性凝胶来确保增加的局部可用性，在所需部位具有较高的SSD可用性，以及对传染性伤口的高功效。